CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

BMS-986253Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D019337 Hematologic Neoplasms NIH 0.45

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0001909 Leukemia HPO 0.41

There is one clinical trial.

Clinical Trials

1 A Randomized Phase 2 Study of Anti-IL-8 Therapy Versus Standard of Care in the Treatment of Hospitalized Patients With Severe COVID-19

This study is for patients that are hospitalized for Coronavirus Disease 2019 (COVID-19). The purpose of this study is to see whether neutralizing interleukin-8 (IL-8) with BMS-986253 can help improve the health condition of participants infected with COVID-19. This is the first in-human study of this investigational product specifically in patients with severe COVID-19. Currently there are no FDA approved medications that improve the chance of survival in patients diagnosed with COVID-19. However there are usual treatments currently being used to help treat COVID-19 patients and BMS-986253 will be compared to these standard of care treatments in this study.

NCT04347226 Solid Tumor Sars-CoV2 Hematological Malignancy Drug: BMS-986253
MeSH:Hematologic Neoplasms
HPO:Hematological neoplasm Leukemia

Primary Outcomes

Description: The time to improvement in the 7-point ordinal scale in patients treated with anti-IL-8 therapy compared to standard of care/controls. Measured from baseline to 2 point or greater improvement in 7-point ordinal scale.

Measure: Time to Improvement in the 7-point ordinal scale

Time: 1 year

Secondary Outcomes

Description: The time to death will be defined as the time from onset from symptoms until death from any cause. Patients who are alive or lost to follow-up at the cut-off date will be censored from this analysis.

Measure: Time to Death

Time: 1 year

Description: The time to intubation will be defined as the time from symptom onset until time of intubation. Any patients already intubated at enrollment will be censored from this analysis.

Measure: Time to Intubation

Time: 1 year

Description: The proportion of patients requiring intensive care unit (ICU) admission will be calculated as the number of patients requiring ICU admission over the course of their hospitalization over the number of evaluable patients.

Measure: Proportion of patients requiring ICU admission

Time: 1 year

Description: Percentage of participants who have died 1 month from the time of start of treatment

Measure: Percentage Rate of Mortality at 1 month

Time: 1 month

Related HPO nodes (Using clinical trials)

HP:0004377: Hematological neoplasm
Genes 347
KRAS PDGFRA IL2RG SRP54 IL2RG NPM1 TET2 FLT3 ITK SMPD1 PRKCD GATA1 KIT RPL11 RUNX1 CALR ATRX TNFRSF1B DCLRE1C SAMD9L EVC2 CD70 BRAF TSR2 SPINK1 RNF43 FASLG ATM CASP10 NRAS BCL10 BUB1 SH2B3 RPS29 CEBPA TP53 CHD7 TINF2 MYSM1 ASXL1 UBE2T CR2 CALR SETBP1 RNASEH2B KLHDC8B MALT1 TINF2 RAF1 STS TERT BCR SRP54 SRP54 TNFSF12 MLH1 RPL18 ELANE DNASE1L3 CBL MAGT1 TYROBP ASXL1 FOXP1 IL7R TCF4 FANCE DNAJC21 RPL15 FANCL KIF11 TP53 COL14A1 MPL HSPA9 IFIH1 SCN11A RPS10 JAK2 DNMT3A CTRC BCL2 LIG4 GINS1 TERC FANCG SF3B1 ELANE NBN NHP2 NUP214 MYC ETV6 CD81 TNFSF12 RNASEH2A BRIP1 BCR BUB1B RPL5 NBN FANCF IGH DNAJC21 TNFRSF1B CCND1 RMRP XRCC2 MSH6 FAS IGH NFKB2 RECQL4 CD28 BUB1B CTLA4 ARHGAP26 RPL35 CBL RAD54L POLE PALB2 GNB1 MDM2 CBFB ADAR ADA RPS17 PARN RPS14 BCR POT1 ABL1 TNFRSF13C FANCE TNFRSF13B ABL1 ICOS TET2 CD27 NFKB1 CALR LIG4 SH3GL1 CD28 PNP F13B USB1 RPL26 RPL31 PTPN11 TP63 RAD51 MPL TET2 PTPN11 ADA NUTM1 STAT3 RAG2 PIGL PRSS1 TET2 NRAS PRF1 FANCA GFI1 ATRX FANCD2 SCN9A TET2 EVC TNFRSF13C BLM RB1 FANCM SH2B3 RTEL1 HAX1 FANCC RAD54B BIRC3 GFI1 RPS15A RPS14 GFI1B RPS19 RPL35A MSH2 TCF4 RFWD3 NF1 TRIP13 PIGA GATA2 ATM SAMD9L DDX41 IGH FANCD2 RASGRP1 CASP10 MLLT10 ADA2 LIG4 MPL RUNX1 BRCA2 CD19 ERCC4 TP53 RMRP RAD51C NUP214 JAK2 SBDS SH2D1A WAS SMARCD2 THPO ZAP70 TREM2 RPS24 KIT JAK2 BLM BRCA1 RNASEH2C MYD88 RFWD3 SAMD9 SLX4 TNFRSF13B SH2B3 GLI1 CHEK2 NPM1 TET2 DKC1 GATA2 MS4A1 ICOS CALR RPS19 DKC1 LIG4 SRSF2 CR2 GATA2 RAG1 PRKCD BCL6 TREX1 RPS27 RPS26 FANCG GBA FANCI LYST SAMHD1 TET2 GATA2 LIG4 PICALM DNAJC21 NTHL1 JAK2 BUB3 TCIRG1 RPS28 FANCA MPL DYNC2LI1 DNMT3A AAGAB FANCC RARA PIK3CA TERC PGM3 MAD2L2 MYD88 MLH1 FANCB MSH6 KRAS TERT RPS7 RUNX1 MCM4 BCL10 XIAP LPP BRCA2 CD19 BRD4 PIK3R1 PTEN NAGS NBEAL2 F13A1 CTC1 SBDS HLA-DRB1 WRAP53 TAL1 EFL1 NOP10 JAK2 FLT3 CEP57 KRAS APC PMS2 WIPF1 JAK2 TERC CTLA4 GATA1 NSUN2 BCL10 XRCC4 NBN SF3B1 FAS PDGFRB RHOH MSH2 RECQL4 TAL2 PIGL RPL27 EP300 CHIC2 CCND1 TET2 GATA2 NUMA1 TERT MPL THPO CREBBP SCN10A CDKN2A ERBB3 SRP72 TERT
Protein Mutations 0
SNP 0
HP:0001909: Leukemia
Genes 187
BLM KRAS PDGFRA RB1 SH2B3 SRP54 NPM1 HAX1 TET2 FLT3 FANCC SMPD1 GFI1 RPS15A GATA1 KIT RPL11 RUNX1 RPS19 RPL35A CALR ATRX MSH2 NF1 SAMD9L TRIP13 EVC2 PIGA GATA2 TSR2 SAMD9L SPINK1 DDX41 FANCD2 ATM NRAS MLLT10 ADA2 BUB1 SH2B3 RPS29 MPL CEBPA RUNX1 ASXL1 TP53 CALR SETBP1 RNASEH2B NUP214 JAK2 SBDS WAS THPO TREM2 STS RPS24 TERT KIT JAK2 BLM BCR SRP54 SRP54 MLH1 RNASEH2C RPL18 MYD88 ELANE SH2B3 CBL GLI1 TYROBP FANCE DKC1 GATA2 DNAJC21 RPL15 KIF11 CALR TP53 SRSF2 MPL GATA2 IFIH1 SCN11A RPS10 TREX1 DNMT3A CTRC RPS27 LIG4 RPS26 FANCG SF3B1 ELANE SAMHD1 TET2 NBN NUP214 ETV6 PICALM RNASEH2A DNAJC21 JAK2 BUB3 TCIRG1 BCR BUB1B RPS28 FANCA RPL5 DYNC2LI1 NBN DNMT3A DNAJC21 MSH6 RARA PIK3CA TERC MYD88 BUB1B ARHGAP26 KRAS RPS7 RUNX1 RPL35 LPP BRCA2 CBL BRD4 GNB1 PIK3R1 CBFB ADAR F13A1 SBDS TAL1 EFL1 RPS17 JAK2 FLT3 RPS14 BCR CEP57 POT1 KRAS ABL1 APC ABL1 PMS2 TET2 WIPF1 JAK2 GATA1 NSUN2 LIG4 SH3GL1 XRCC4 F13B RPL26 RPL31 MPL PTPN11 PDGFRB NUTM1 TAL2 PIGL PIGL PRSS1 TET2 RPL27 EP300 NRAS CHIC2 TET2 GATA2 NUMA1 TERT GFI1 MPL THPO CREBBP SCN10A SCN9A ERBB3 EVC
Protein Mutations 56
C282Y C481S D816V D835Y E255K E255V F317C F317L F317S F317V F31I F359C F359V G250E G71R H369P H63D L248R L248V L265P L858R N291S N682S P13K P140K P1446A P4503A Q12H Q252H R132C R132G R132H R132L R132S R132V R140L R140Q R140W R172G R172K R172M R172S R172W S1612C S9333A T315A T315I T351I T790M V158M V299L V57I V600E V617F V66M Y253H
SNP 17
rs10509681 rs11572080 rs12459419 rs172378 rs2032582 rs230561 rs25531 rs3816527 rs396991 rs429358 rs4880 rs4958351 rs6190 rs628031 rs7412 rs776746 rs904627